Role of amylin in insulin secretion and action in humans: Antagonist studies across the spectrum of insulin sensitivity

Kieren Mather, Giancarlo Paradisi, Rosalind Leaming, Ginger Hook, Helmut O. Steinberg, Naomi Fineberg, Rochelle Hanley, Alain D. Baron

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background. Amylin is a peptide co-secreted with insulin by pancreatic β-cells. A role for amylin in the pathogenesis of type 2 diabetes mellitus (DM2) has been suggested by in vitro and in vivo studies indicating an effect of amylin to cause insulin resistance and/or inhibit insulin secretion. Methods. We have determined the effect of endogenous amylin on insulin secretion and insulin action in humans by performing 4-h hyperglycemic clamps during infusion of placebo or a specific amylin receptor antagonist (ARA) in paired, double-blinded, crossover studies. We studied nine healthy lean, ten healthy obese (BMI>27) and ten obesity-matched DM2 subjects. Results. Infusion of ARA alone had no effect on basal insulin, glucose or glucose turnover in any group. Under combined hyperglycemia and ARA infusion, lean subjects displayed a 32% augmentation in insulin levels [AUC 33 565 ± 3556 (placebo) to 44 562 ± 1379 (ARA) pmol/l/min, p<0.01]. The concomitant increase in glucose disposal rate (GDR) was proportionate, indicating no change in insulin sensitivity (ISI 27.7 ± 2.7 vs 27.3 ± 2.1, p = NS). In obese subjects, basal insulin and the rise in insulin during the clamp were greater (AUC I 44% increase from 82 054 ± 15 407 to 117 922 ± 27 085, p < 0.01), and also accompanied by a proportionate rise in GDR reflecting an unchanged insulin sensitivity (ISI 12.1 ± 2.9 vs 10.8 ± 3.0, p = NS). In lean and obese subjects, the C-peptide response to hyperglycemia was also augmented by ARA (p = 0.007). No effect of ARA on insulin secretion or action was observed in diabetic subjects. Conclusions. The present data are consistent with an effect of endogenous amylin on the β-cell to modulate and/or restrain insulin secretion, and indicate that endogenous amylin does not affect insulin action. These observations provide the first human evidence that amylin plays a role in the modulation of insulin secretion.

Original languageEnglish
Pages (from-to)118-126
Number of pages9
JournalDiabetes/Metabolism Research and Reviews
Volume18
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Islet Amyloid Polypeptide
Islet Amyloid Polypeptide Receptor
Insulin Resistance
Insulin
Glucose
Hyperglycemia
Area Under Curve
Insulin Antagonists
Clamping devices
Placebos
C-Peptide
Cross-Over Studies
Type 2 Diabetes Mellitus
Obesity
Medical problems

Keywords

  • Amylin
  • Glucose disposal rate
  • Hyperglycemic clamp
  • Insulin resistance
  • Insulin sensitivity

ASJC Scopus subject areas

  • Endocrinology
  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Role of amylin in insulin secretion and action in humans : Antagonist studies across the spectrum of insulin sensitivity. / Mather, Kieren; Paradisi, Giancarlo; Leaming, Rosalind; Hook, Ginger; Steinberg, Helmut O.; Fineberg, Naomi; Hanley, Rochelle; Baron, Alain D.

In: Diabetes/Metabolism Research and Reviews, Vol. 18, No. 2, 2002, p. 118-126.

Research output: Contribution to journalArticle

Mather, Kieren ; Paradisi, Giancarlo ; Leaming, Rosalind ; Hook, Ginger ; Steinberg, Helmut O. ; Fineberg, Naomi ; Hanley, Rochelle ; Baron, Alain D. / Role of amylin in insulin secretion and action in humans : Antagonist studies across the spectrum of insulin sensitivity. In: Diabetes/Metabolism Research and Reviews. 2002 ; Vol. 18, No. 2. pp. 118-126.
@article{d17d8f683a254ceaafd90e1af8d506ba,
title = "Role of amylin in insulin secretion and action in humans: Antagonist studies across the spectrum of insulin sensitivity",
abstract = "Background. Amylin is a peptide co-secreted with insulin by pancreatic β-cells. A role for amylin in the pathogenesis of type 2 diabetes mellitus (DM2) has been suggested by in vitro and in vivo studies indicating an effect of amylin to cause insulin resistance and/or inhibit insulin secretion. Methods. We have determined the effect of endogenous amylin on insulin secretion and insulin action in humans by performing 4-h hyperglycemic clamps during infusion of placebo or a specific amylin receptor antagonist (ARA) in paired, double-blinded, crossover studies. We studied nine healthy lean, ten healthy obese (BMI>27) and ten obesity-matched DM2 subjects. Results. Infusion of ARA alone had no effect on basal insulin, glucose or glucose turnover in any group. Under combined hyperglycemia and ARA infusion, lean subjects displayed a 32{\%} augmentation in insulin levels [AUC 33 565 ± 3556 (placebo) to 44 562 ± 1379 (ARA) pmol/l/min, p<0.01]. The concomitant increase in glucose disposal rate (GDR) was proportionate, indicating no change in insulin sensitivity (ISI 27.7 ± 2.7 vs 27.3 ± 2.1, p = NS). In obese subjects, basal insulin and the rise in insulin during the clamp were greater (AUC I 44{\%} increase from 82 054 ± 15 407 to 117 922 ± 27 085, p < 0.01), and also accompanied by a proportionate rise in GDR reflecting an unchanged insulin sensitivity (ISI 12.1 ± 2.9 vs 10.8 ± 3.0, p = NS). In lean and obese subjects, the C-peptide response to hyperglycemia was also augmented by ARA (p = 0.007). No effect of ARA on insulin secretion or action was observed in diabetic subjects. Conclusions. The present data are consistent with an effect of endogenous amylin on the β-cell to modulate and/or restrain insulin secretion, and indicate that endogenous amylin does not affect insulin action. These observations provide the first human evidence that amylin plays a role in the modulation of insulin secretion.",
keywords = "Amylin, Glucose disposal rate, Hyperglycemic clamp, Insulin resistance, Insulin sensitivity",
author = "Kieren Mather and Giancarlo Paradisi and Rosalind Leaming and Ginger Hook and Steinberg, {Helmut O.} and Naomi Fineberg and Rochelle Hanley and Baron, {Alain D.}",
year = "2002",
doi = "10.1002/dmrr.263",
language = "English",
volume = "18",
pages = "118--126",
journal = "Diabetes/Metabolism Research and Reviews",
issn = "1520-7552",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Role of amylin in insulin secretion and action in humans

T2 - Antagonist studies across the spectrum of insulin sensitivity

AU - Mather, Kieren

AU - Paradisi, Giancarlo

AU - Leaming, Rosalind

AU - Hook, Ginger

AU - Steinberg, Helmut O.

AU - Fineberg, Naomi

AU - Hanley, Rochelle

AU - Baron, Alain D.

PY - 2002

Y1 - 2002

N2 - Background. Amylin is a peptide co-secreted with insulin by pancreatic β-cells. A role for amylin in the pathogenesis of type 2 diabetes mellitus (DM2) has been suggested by in vitro and in vivo studies indicating an effect of amylin to cause insulin resistance and/or inhibit insulin secretion. Methods. We have determined the effect of endogenous amylin on insulin secretion and insulin action in humans by performing 4-h hyperglycemic clamps during infusion of placebo or a specific amylin receptor antagonist (ARA) in paired, double-blinded, crossover studies. We studied nine healthy lean, ten healthy obese (BMI>27) and ten obesity-matched DM2 subjects. Results. Infusion of ARA alone had no effect on basal insulin, glucose or glucose turnover in any group. Under combined hyperglycemia and ARA infusion, lean subjects displayed a 32% augmentation in insulin levels [AUC 33 565 ± 3556 (placebo) to 44 562 ± 1379 (ARA) pmol/l/min, p<0.01]. The concomitant increase in glucose disposal rate (GDR) was proportionate, indicating no change in insulin sensitivity (ISI 27.7 ± 2.7 vs 27.3 ± 2.1, p = NS). In obese subjects, basal insulin and the rise in insulin during the clamp were greater (AUC I 44% increase from 82 054 ± 15 407 to 117 922 ± 27 085, p < 0.01), and also accompanied by a proportionate rise in GDR reflecting an unchanged insulin sensitivity (ISI 12.1 ± 2.9 vs 10.8 ± 3.0, p = NS). In lean and obese subjects, the C-peptide response to hyperglycemia was also augmented by ARA (p = 0.007). No effect of ARA on insulin secretion or action was observed in diabetic subjects. Conclusions. The present data are consistent with an effect of endogenous amylin on the β-cell to modulate and/or restrain insulin secretion, and indicate that endogenous amylin does not affect insulin action. These observations provide the first human evidence that amylin plays a role in the modulation of insulin secretion.

AB - Background. Amylin is a peptide co-secreted with insulin by pancreatic β-cells. A role for amylin in the pathogenesis of type 2 diabetes mellitus (DM2) has been suggested by in vitro and in vivo studies indicating an effect of amylin to cause insulin resistance and/or inhibit insulin secretion. Methods. We have determined the effect of endogenous amylin on insulin secretion and insulin action in humans by performing 4-h hyperglycemic clamps during infusion of placebo or a specific amylin receptor antagonist (ARA) in paired, double-blinded, crossover studies. We studied nine healthy lean, ten healthy obese (BMI>27) and ten obesity-matched DM2 subjects. Results. Infusion of ARA alone had no effect on basal insulin, glucose or glucose turnover in any group. Under combined hyperglycemia and ARA infusion, lean subjects displayed a 32% augmentation in insulin levels [AUC 33 565 ± 3556 (placebo) to 44 562 ± 1379 (ARA) pmol/l/min, p<0.01]. The concomitant increase in glucose disposal rate (GDR) was proportionate, indicating no change in insulin sensitivity (ISI 27.7 ± 2.7 vs 27.3 ± 2.1, p = NS). In obese subjects, basal insulin and the rise in insulin during the clamp were greater (AUC I 44% increase from 82 054 ± 15 407 to 117 922 ± 27 085, p < 0.01), and also accompanied by a proportionate rise in GDR reflecting an unchanged insulin sensitivity (ISI 12.1 ± 2.9 vs 10.8 ± 3.0, p = NS). In lean and obese subjects, the C-peptide response to hyperglycemia was also augmented by ARA (p = 0.007). No effect of ARA on insulin secretion or action was observed in diabetic subjects. Conclusions. The present data are consistent with an effect of endogenous amylin on the β-cell to modulate and/or restrain insulin secretion, and indicate that endogenous amylin does not affect insulin action. These observations provide the first human evidence that amylin plays a role in the modulation of insulin secretion.

KW - Amylin

KW - Glucose disposal rate

KW - Hyperglycemic clamp

KW - Insulin resistance

KW - Insulin sensitivity

UR - http://www.scopus.com/inward/record.url?scp=0036250177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036250177&partnerID=8YFLogxK

U2 - 10.1002/dmrr.263

DO - 10.1002/dmrr.263

M3 - Article

C2 - 11994903

AN - SCOPUS:0036250177

VL - 18

SP - 118

EP - 126

JO - Diabetes/Metabolism Research and Reviews

JF - Diabetes/Metabolism Research and Reviews

SN - 1520-7552

IS - 2

ER -